CHO-K1/Human P2Y12 Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0185A | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
The P2Y12 receptor is a G protein-coupled receptor primarily activated by ADP, belonging to the Gi-coupled subgroup of the purinergic P2Y receptor family. It is highly expressed on the surface of platelets and serves as the central driver of ADP-induced platelet aggregation, playing a critical role in physiological hemostasis and arterial thrombosis. Additionally, this receptor is distributed on microglial cells in the central nervous system and on vascular smooth muscle cells, where it participates in regulating neuroinflammation and vascular injury responses. P2Y12 is a key target for antiplatelet drugs (such as clopidogrel and ticagrelor), widely used in the prevention and treatment of thrombotic diseases including myocardial infarction and stroke.
Screeningbio’s CHO-K1/Human P2Y12 cell line overexpress P2RY12 and is designed to detect inhibition in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Human |
HGNC Symbol | P2RY12 |
Accession Number | SNB-G-0185A |
Parental Line | CHO-K1 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
The P2Y12 receptor is a G protein-coupled receptor primarily activated by ADP, belonging to the Gi-coupled subgroup of the purinergic P2Y receptor family. It is highly expressed on the surface of platelets and serves as the central driver of ADP-induced platelet aggregation, playing a critical role in physiological hemostasis and arterial thrombosis.
Additionally, this receptor is distributed on microglial cells in the central nervous system and on vascular smooth muscle cells, where it participates in regulating neuroinflammation and vascular injury responses. P2Y12 is a key target for antiplatelet drugs (such as clopidogrel and ticagrelor), widely used in the prevention and treatment of thrombotic diseases including myocardial infarction and stroke.